Connect
MJA
MJA

Correction: Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Haemostasis and Thrombosis

Ross I Baker, Paul B Coughlin, Hatem H Salem, Alex S Gallus, Paul L Harper and Erica M Wood
Med J Aust 2005; 182 (1): 48.
Published online: 3 January 2005

Re: “Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Haemostasis and Thrombosis”, by Ross I Baker, Paul B Coughlin, Alex S Gallus, et al on behalf of the Warfarin Reversal Consensus Group (Med J Aust 2004; 181: 492-497). In Box 5, an asterisk in the Box title should have attributed Prothombinex-HT to CSL Limited, the manufacturer of all plasma-derived therapeutic products fractionated from Australian plasma.

  • Ross I Baker1
  • Paul B Coughlin2
  • Hatem H Salem3
  • Alex S Gallus4
  • Paul L Harper5
  • Erica M Wood6

  • 1 Thrombosis and Haemophilia Service, Royal Perth Hospital, Perth, WA.
  • 2 Monash University, Box Hill Hospital, Box Hill, VIC.
  • 3 SouthPath, Flinders Medical Centre, Bedford Park, SA.
  • 4 Auckland City Hospital, Auckland, New Zealand.
  • 5 Australian Red Cross Blood Service, Southbank, VIC.

Correspondence: 

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.